↓ Skip to main content
What is this page? Embed badge

Lung Cancer and Personalized Medicine

Overview of attention for book
Cover of 'Lung Cancer and Personalized Medicine'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Lung Cancer Statistics.
  3. Altmetric Badge
    Chapter 2 Epidemiology of Lung Cancer.
  4. Altmetric Badge
    Chapter 3 Lung Cancer in Never Smokers.
  5. Altmetric Badge
    Chapter 4 Immune Therapy.
  6. Altmetric Badge
    Chapter 5 Anti-angiogenesis in Personalized Therapy of Lung Cancer.
  7. Altmetric Badge
    Chapter 6 Target Therapy in Lung Cancer.
  8. Altmetric Badge
    Chapter 7 Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update.
  9. Altmetric Badge
    Chapter 8 KRAS-Mutant Lung Cancers in the Era of Targeted Therapy.
  10. Altmetric Badge
    Chapter 9 Anaplastic Lymphoma Kinase (ALK) Signaling in Lung Cancer.
  11. Altmetric Badge
    Chapter 10 Chemotherapy Resistance in Lung Cancer.
  12. Altmetric Badge
    Chapter 11 Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.
Attention for Chapter 10: Chemotherapy Resistance in Lung Cancer.
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog

Readers on

mendeley
104 Mendeley
Summary News Blogs
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Chemotherapy Resistance in Lung Cancer.
Chapter number 10
Book title
Lung Cancer and Personalized Medicine
Published in
Advances in experimental medicine and biology, December 2015
DOI 10.1007/978-3-319-24223-1_10
Pubmed ID
26667345
Book ISBNs
978-3-31-924221-7, 978-3-31-924223-1
Authors

Eric S. Kim, Kim, Eric S.

Editors

Aamir Ahmad, Shirish Gadgeel

Abstract

Despite a growing interest in development of non-cytotoxic targeted agents, systemic chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). However, chemotherapy resistance limits our ability to effectively treat advanced lung cancer. Some lung tumors are intrinsically resistant to chemotherapy, and in virtually all cases, even the initial responders rapidly develop acquired resistance. While targeting histology could result in enhanced tumor sensitivity to a particular chemotherapeutic agent, better understanding of molecular determinants of chemotherapy sensitivity/resistance would be critically important. Development of predictive biomarkers to personalize chemotherapeutic agents and combining novel agents targeting specific resistance pathways with standard chemotherapy could be some promising strategies to overcome chemotherapy resistance in lung cancer. In this chapter, we will discuss some key mechanisms of resistance for commonly used chemotherapeutic agents in lung cancer.

View on publisher site
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 1 <1%
Unknown 103 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 16 15%
Student > Bachelor 12 12%
Student > Ph. D. Student 11 11%
Student > Master 10 10%
Student > Doctoral Student 6 6%
Other 8 8%
Unknown 41 39%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 21 20%
Medicine and Dentistry 14 13%
Agricultural and Biological Sciences 10 10%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Nursing and Health Professions 3 3%
Other 7 7%
Unknown 41 39%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 April 2018.
All research outputs
#2,469,510
of 22,862,742 outputs
Outputs from Advances in experimental medicine and biology
#373
of 4,950 outputs
Outputs of similar age
#44,077
of 390,260 outputs
Outputs of similar age from Advances in experimental medicine and biology
#43
of 417 outputs
Altmetric has tracked 22,862,742 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,950 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 390,260 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 417 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.

This page is provided by Altmetric.